Study of the common wormwood allergoid
- Authors: Esaulova D.R.1, Nechay K.O.1, Andreev A.I.1, Andreev I.V.1, Latysheva T.V.1, Setdikova N.K.1, Latysheva E.A.1,2, Gudima G.O.1,3, Smirnov V.V.1,4, Martynov А.I.1, Khaitov M.R.1,2
-
Affiliations:
- National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
- The Russian National Research Medical University named after N.I. Pirogov
- Federal Scientific and Clinical Center for Specialized Types of Medical Care and Major Technologies of the Federal Medical and Biological Agency
- The First Sechenov Moscow State Medical University (Sechenov University)
- Issue: Vol 21, No 4 (2024)
- Pages: 469-478
- Section: Original studies
- URL: https://journals.rcsi.science/raj/article/view/278999
- DOI: https://doi.org/10.36691/RJA16964
- ID: 278999
Cite item
Abstract
BACKGROUND: Allergens from the pollen of wormwood (Latin: Artemisia absinthium) are among the most dangerous in terms of allergization in central Russia, Europe and a number of other regions. The use of allergoids created using glutaraldehyde instead of native allergen extracts is due to the reduced risk of developing allergic reactions while maintaining immunogenicity and eliminating the highly toxic element formalin from the production process, which makes allergoids safer for use in allergen-specific immunotherapy.
AIM: Obtaining an allergoid from wormwood pollen by treatment with glutaraldehyde to evaluate its properties prior to preclinical testing.
MATERIALS AND METHODS: Purified extract of wormwood pollen, isolated by defatting and water-salt extraction, was dissolved in phosphate-buffered saline (PBS) pH 7.5, after which it was polymerized in 0.1 % glutaraldehyde solution. Stabilization was performed with sodium borohydride solution. The extract and allergoid of wormwood pollen were studied using chromatographic analysis and competitive enzyme-linked immunosorbent assay (ELISA). Then, intraperitoneal immunization with the obtained allergoid was carried out in CBA × C57Bl/6 (F1) mice.
RESULTS: After evaluation of the specific allergenic activity using competitive immune assay ELISA with biotinylated extract of wormwood pollen allergen, it was shown that the 50 % inhibition point for the allergoid is determined at a drug concentration of 0.03 mg/ml, and for the allergen – already at 0.0008 mg/ml. Consequently, the allergenicity of wormwood pollen allergoid is significantly reduced compared to that of the original extract. In addition, the immunogenic activity of the obtained allergoid was confirmed in mice: the average optical density of the ELISA reaction, indicating the amount of IgG, in the group immunized with the allergoid was more than at least 1.5 times higher than the values for the allergen extract.
CONCLUSIONS: During the work, an extract containing allergens of wormwood pollen was obtained. An allergoid was obtained on its basis by polymerization with glutaraldehyde. The obtained allergoid has a high molecular weight (the range shifted to 44–66 kDa), while it has low allergenic activity, in comparison with the original extract, and also retains immunogenicity. In this regard, this allergoid can become the basis for obtaining new ASIT treatments.
Full Text
##article.viewOnOriginalSite##About the authors
Daria R. Esaulova
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Author for correspondence.
Email: esaulova.d.r@gmail.com
ORCID iD: 0000-0003-0283-5637
SPIN-code: 4399-8631
Russian Federation, Moscow
Ksenia O. Nechay
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: xenya.ne4ay2016@yandex.ru
ORCID iD: 0000-0001-6052-9721
SPIN-code: 7206-6660
Russian Federation, Moscow
Alexandr I. Andreev
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: cahek_ahdreeb@mail.ru
ORCID iD: 0000-0002-6257-6289
SPIN-code: 7126-4748
Russian Federation, Moscow
Igor V. Andreev
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: iva66@list.ru
ORCID iD: 0000-0001-6162-6726
SPIN-code: 8072-9669
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowTatyana V. Latysheva
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: tv.latysheva@nrcii.ru
ORCID iD: 0000-0003-1508-0640
SPIN-code: 8929-7644
MD, Dr. Sci. (Medicine), Professor
Russian Federation, MoscowNailya Kh. Setdikova
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: nh.setdikova@nrcii.ru
ORCID iD: 0000-0003-2587-7928
SPIN-code: 6339-6945
MD, Dr. Sci. (Medicine)
Russian Federation, MoscowElena A. Latysheva
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; The Russian National Research Medical University named after N.I. Pirogov
Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN-code: 2063-7973
MD, Dr. Sci. (Medicine)
Russian Federation, Moscow; MoscowGeorgii O. Gudima
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Major Technologies of the Federal Medical and Biological Agency
Email: g.gudima@nrcii.ru
ORCID iD: 0000-0003-2864-6949
SPIN-code: 5307-9425
Dr. Sci. (Biology), Professor
Russian Federation, Moscow; MoscowValery V. Smirnov
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; The First Sechenov Moscow State Medical University (Sechenov University)
Email: vall@mail.mipt.ru
ORCID iD: 0000-0002-8232-6682
SPIN-code: 4171-3871
Dr. Sci. (Pharmacy)
Russian Federation, Moscow; MoscowАlexander I. Martynov
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: immune48@mail.ru
ORCID iD: 0000-0001-9761-8058
SPIN-code: 5829-5580
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowMusa R. Khaitov
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; The Russian National Research Medical University named after N.I. Pirogov
Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803
MD, Dr. Sci. (Medicine), Professor, corresponding member of Russian Academy of Sciences
Russian Federation, Moscow; MoscowReferences
- Bala AM, Gudima GO, Khaitov MR. Molecular mechanisms of allergy. In: Khaitov MR, Shilovsky IP. Anticytokine therapy of allergic diseases: molecular immunological mechanisms and clinical bases. Moscow: Media Sfera, 2021. P. 66–125. (In Russ).
- Avoyan GE, Kulaga OS, Nechay KO, et al. Development and experimental evaluation of the bee venom allergoid. Immunologiya. 2023;44(3):345–357. (In Russ). doi: 10.33029/0206-4952-2023-44-3-345-357
- Smirnov VV, Gudima GO, Kudlay DA, Shilovsky IP. Clinical pharmacokinetics of monoclonal antibodies and small interfering RNAs. In: Khaitov MR, Shilovsky IP. Anticytokine therapy of allergic diseases: molecular immunological mechanisms and clinical bases. Moscow: Media Sfera, 2021. P. 218–240. (In Russ).
- Kim EH, Keet CA, Virkud YV, et al. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children. J Allergy Clin Immunol. 2023;151(6):1558–1565.e6. doi: 10.1016/j.jaci.2023.01.036
- Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–1282.e1-6. doi: 10.1016/j.jaci.2014.11.005
- Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc. 2007;28(1):35–39. doi: 10.2500/aap.2007.28.2919
- Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–1079. doi: 10.1016/j.jaci.2005.08.027
- Cafone J, Capucilli P, Hill DA, Spergel JM. Eosinophilic esophagitis during sublingual and oral allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2019;19(4):350–357. doi: 10.1097/ACI.0000000000000537
- Osterman LA. Methods of Protein and Nucleic Acid Research: Electrophoresis and Ultracentrifugation (practical guide). Moscow: Nauka, 1981. (In Russ).
- General pharmacopoeia article “Determination of protein. OFS.1.2.3.0012.15”. State Pharmacopeia of the Russian Federation. XIV edition. Moscow, 2018. (In Russ). Available from: https://docs.cntd.ru/document/554031266. Accessed: 12.04.2012.
- Kozlov IB, Lebedin MYu, Gudima GO, et al. Photoregulated oligonucleotide detachment as a way to improve the efficiency of polymerase chain reaction with reverse transcription for analysis at the single cell level. Immunologiya. 2021;46(6):662–669. (In Russ). doi: 10.33029/0206-4952-2021-42-6-662-669
- Kursakov SV, Kuznetsova EG, Kuryleva OM, et al. Development and validation of a method for glucosaminyl muramyl dipeptide determining in aqueous solutions by high performance liquid chromatography. Immunology. 2020;41(1):74–82. (In Russ). doi: 10.33029/0206-4952-2020-41-1-74-82
- Versteeg SA, Bulder I, Himly M, van Ree R. Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity but Retained Immunogenicity. World Allergy Organ J. 2011;4(3):113–120. doi: 10.1097/WOX.0b013e3182228a39
- Gupta P, Saltoun C. Allergen immunotherapy: definition, indications, and reactions. Allergy and Asthma Proceedings. 2019;40(6):369–371. doi: 10.2500/aap.2019.40.4249
- Carnes J, Gallego M, Moya R, Iraola V. Allergoids for allergy treatment. Allergoids for Allergy Treatment. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):110–119. doi: 10.2174/1872213X12666180221155908
- Moreno Aguilar C, Eguiluz-Gracia I, Planelles Asensio I, Rondón C. Allergen immunotherapy: the need for higher quality clinical trials. Allergol Immunopathol (Madr). 2016;44(5):398–400. doi: 10.1016/j.aller.2016.08.008
Supplementary files
